Literature DB >> 12473405

Mirtazapine in Parkinsonian tremor.

P H Gordon, S L Pullman, E D Louis, S J Frucht, S Fahn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12473405     DOI： 10.1016/s1353-8020(02)00011-1

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN： 1353-8020            Impact factor:   4.891


× No keyword cloud information.
  10 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

2.  The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.

Authors:  Adjia Hamadjida; Stephen G Nuara; Nicolas Veyres; Imane Frouni; Cynthia Kwan; Lamia Sid-Otmane; Mery-Jane Harraka; Jim C Gourdon; Philippe Huot
Journal:  Psychopharmacology (Berl)       Date:  2017-01-27       Impact factor: 4.530

3.  Mirtazapine in the treatment of essential tremor: an open-label, observer-blind study.

Authors:  Davide Uccellini; G Grampa; I La Spina; D Nasuelli; I Neromante; L Politini; F Reverberi; D Porazzi; V Carli; G Camardese
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

Review 4.  Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Petros Skapinakis; Eleni Bakola; Georgia Salanti; Glyn Lewis; Athanasios P Kyritsis; Venetsanos Mavreas
Journal:  BMC Neurol       Date:  2010-06-21       Impact factor: 2.474

Review 5.  Non-dopaminergic treatments for motor control in Parkinson's disease.

Authors:  Susan H Fox
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

Review 6.  The serotonergic system in motor and non-motor manifestations of Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox
Journal:  Exp Brain Res       Date:  2013-06-28       Impact factor: 1.972

7.  Anxiety and depression in Parkinson's disease.

Authors:  Atbin Djamshidian; Joseph H Friedman
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.598

8.  Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease.

Authors:  Nathan A Holtz; Stephanie E Tedford; Amanda L Persons; Salvatore A Grasso; T Celeste Napier
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-05-20       Impact factor: 5.067

Review 9.  Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action.

Authors:  Tay Kay Yaw; Susan H Fox; Anthony E Lang
Journal:  Mov Disord Clin Pract       Date:  2015-12-30

10.  Mirtazapine has a therapeutic potency in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice model of Parkinson's disease.

Authors:  Naoto Kadoguchi; Shinji Okabe; Yukio Yamamura; Misaki Shono; Tatsuya Fukano; Akie Tanabe; Hironori Yokoyama; Jiro Kasahara
Journal:  BMC Neurosci       Date:  2014-06-25       Impact factor: 3.288
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.